Clinical trial NCT01227759: Tyrosur® Gel-Investigation on Wound Healing Efficacy
Official title: A Phase IIa, Single-center, Randomized, Observer-blind Trial With Intraindividual Comparison of Treated Versus Untreated to Assess the Wound Healing Efficacy of Topical Tyrosur® Gel
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Wounds
Wound Healing
Lead sponsor: Engelhard Arzneimittel GmbH & Co.KG
Sponsor class: INDUSTRY
First posted: 2010-10-25
Enrollment: 33
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This IIa study with intraindividual comparison of treated versus untreated to assess the wound healing efficacy of Tyrosur® Gel after experimental impairment of the skin using an abrasive wound healing model.

Detailed description: This is a single-center, randomized, observer-blind phase IIa study with intraindividual comparison of treated versus untreated to assess the wound healing efficacy of Tyrosur® Gel after experimental impairment of the skin using an abrasive wound healing model.

In the investigation two small, superficial, abrasive wounds will be induced on the right forearm and one on the left forearm of each subject using a sterile surgical hand brush. These wounds will then be treated with the investigational products. The wound healing will be clinically assessed and photographs will be taken for documentation.

Eligibility criteria: Inclusion Criteria:

* Men and women aged 18 years or older with healthy skin in the test area
* The physical examination must be without disease findings unless the investigator considers an abnormality to be irrelevant for the outcome of the clinical trial;
* Written informed consent obtained.

Exclusion Criteria:

* acne, suntan, eczema, hyperpigmentation or tattoos in the test fields;
* dark-skinned persons whose skin color prevents ready assessment of skin reactions;
* subjects with diabetes, psoriasis or lichen ruber planus;
* history of wound-healing complications, or keloid and hypertrophic scarring;
* evidence of drug or alcohol abuse;
* pregnancy or nursing;
* symptoms of a clinically significant illness that may influence the outcome of the trial in the four weeks before and during the trial;
* known allergic reactions to components of the investigational product/s;
* treatment with systemic or locally acting medications which might counter or influence the trial aim within two weeks before the baseline visit (e.g. antihistamines or glucocorticosteroids);
* contraindications according to summary of product characteristics;

Primary outcomes:
measure: Clinical assessment of the wound healing efficacy of verum compared to untreated using a score for wound healing rates
timeFrame: 12 days
Secondary outcomes:
measure: Clinical assessment of the wound healing efficacy of the vehicle compared to untreated using a score for wound healing rates; Photo documentation of the wound healing efficacy
timeFrame: 12 days
Other outcomes:
Locations:
Study officials:
affiliation: Managing director bioskin, Hamburg Germany
name: Walter Wigger-Alberti, MD
role: PRINCIPAL_INVESTIGATOR
References: